EE694 Evaluation of Healthcare Resource Utilization and Cost Among First-Line Patients Receiving Ibrutinib Vs Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Commercial Claims Database Analysisdoi:10.1016/j.jval.2023.09.959B. Muluneh...
e19049#Background:Acala and zanu are 2ndgeneration Bruton tyrosine kinase inhibitors (BTKis) that have demonstrated improved safety profiles vs 1stgeneration BTKi ibrutinib in clinical trials. While head-to-head comparison of zanu vs acala is lacking, a recent meta-analysis of clinical trials ...